Sangamo Therapeutics (NASDAQ:SGMO) & Senti Biosciences (NASDAQ:SNTI) Head-To-Head Comparison

Senti Biosciences (NASDAQ:SNTI) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.

Valuation & Earnings

This table compares Senti Biosciences and Sangamo Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$2.56 million	7.03	-$71.06 million	($15.56)	-0.25
Sangamo Therapeutics	$52.29 million	10.21	-$257.83 million	($0.75)	-3.41

Senti Biosciences has higher earnings, but lower revenue than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Senti Biosciences and Sangamo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-154.84%	-77.42%
Sangamo Therapeutics	-257.87%	-264.16%	-107.24%

Analyst Ratings

This is a summary of current ratings and price targets for Senti Biosciences and Sangamo Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	0	0	1	0	3.00
Sangamo Therapeutics	0	1	3	0	2.75

Senti Biosciences presently has a consensus price target of $10.00, indicating a potential upside of 155.10%. Sangamo Therapeutics has a consensus price target of $7.00, indicating a potential upside of 173.44%. Given Sangamo Therapeutics’ higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Senti Biosciences.

Insider and Institutional Ownership

25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 15.9% of Senti Biosciences shares are held by company insiders. Comparatively, 2.8% of Sangamo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Senti Biosciences has a beta of 2.69, indicating that its share price is 169% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.

Summary

Senti Biosciences beats Sangamo Therapeutics on 8 of the 14 factors compared between the two stocks.

About Senti Biosciences

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.